Abstract: The present invention relates to novel chemical compounds, to methods for synthesis of such compounds, and to the use of these novel compounds in the synthesis of other chemical compounds that, inter alia, may be used in the treatment of sexual dysfunction, and for eliciting enhancing effects on sexual behavior. The invention also relates to remarkable biological properties of the novel compounds in their capacity of inducing aggressive behavior.

Abstract: The present invention relates to novel chemical compounds, to methods for synthesis of such compounds, and to the use of these novel compounds in the synthesis of other chemical compounds that, inter alia, may be used in the treatment of sexual dysfunction, and for eliciting enhancing effects on sexual behavior. The invention also relates to remarkable biological properties of the novel compounds in their capacity of inducing aggressive behavior.

Abstract: The invention relates to methods of treatment comprising administering a compound of the general formula (1): to a patient or a healthy individual.

Abstract: The invention relates to methods of treatment comprising administering a compound of the general formula (1): to a patient or a healthy individual.

Abstract: A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.

Abstract: The invention features pharmaceutical compositions that include hydroxyguanidines. The compositions can be used, for example, for treating or preventing ischemic diseases, hypoxia,or arrhythmias.

Abstract: Novel DNA fragments encoding novel polypeptide having properties of melantropic hormone receptors, especially DNA fragments encoding melanocyte stimulating hormone receptors (MSH receptors), as well as polypeptide which are MSH receptors, are disclosed. The use and engineering of melanotropic hormone receptor DNA and polypeptide for production of monoclonal antibodies for diagnostic and therapeutic purposes, as well as the engineering of drugs, cell lines, vectors and DNA for therapeutic and diagnostic purposes are also disclosed. Also disclosed are methods for therapy and diagnosis of malignant melanoma, skin cancer, vitiligo, pyretic condition, inflammatory condition, nociceptive condition, catatonic condition, impaired memory condition, reduced or increased skin tanning, pigmentation condition, epilepsy and nerve damage, using the DNA fragments, polypeptide and antibodies. Methods for selecting substances which interact with the receptors are also disclosed.

Abstract: Novel DNA fragments encoding novel polypeptides having properties of melanotropic hormone receptors, especially DNA molecules encoding melanocyte stimulating hormone receptors (MSH receptors), as well as polypeptides which are MSH receptors, are disclosed. The use and engineering of melanotropic hormone receptor DNA and polypeptides for production of monoclonal antibodies for diagnostic and therapeutic purposes, as well as the engineering of drugs, cell lines, vectors, and DNA for therapeutic and diagnostic purposes are also disclosed.